| 1 | Monolignol export by diffusion down a polymerization-induced concentration gradient | 7.6 | 45 | Citations (PDF) |
| 2 | DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation | 11.3 | 8 | Citations (PDF) |
| 3 | Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia | 11.3 | 21 | Citations (PDF) |
| 4 | Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin | 4.7 | 4 | Citations (PDF) |
| 5 | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia | 3.9 | 48 | Citations (PDF) |
| 6 | What Drives Innovation: The Canadian Touch on Liposomal Therapeutics | 5.2 | 22 | Citations (PDF) |
| 7 | Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use | 4.7 | 24 | Citations (PDF) |
| 8 | Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461 | 3.5 | 6 | Citations (PDF) |
| 9 | Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response | 4.5 | 37 | Citations (PDF) |
| 10 | Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor | 11.3 | 15 | Citations (PDF) |
| 11 | Developing liposomal nanomedicines for treatment of patients with neuroblastoma 2018, , 361-411 | | 4 | Citations (PDF) |
| 12 | CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours | 14.1 | 382 | Citations (PDF) |
| 13 | In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization | 4.7 | 7 | Citations (PDF) |
| 14 | Optimization of liposomal topotecan for use in treating neuroblastoma | 2.8 | 18 | Citations (PDF) |
| 15 | A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer | 11.3 | 35 | Citations (PDF) |
| 16 | Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status | 2.6 | 30 | Citations (PDF) |
| 17 | <i>In Vivo</i> Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target | 6.4 | 10 | Citations (PDF) |
| 18 | A Perspective – can copper complexes be developed as a novel class of therapeutics? | 3.2 | 149 | Citations (PDF) |
| 19 | Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles | 4.2 | 4 | Citations (PDF) |
| 20 | Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent | 5.4 | 55 | Citations (PDF) |
| 21 | Development of a copper-clioquinol formulation suitable for intravenous use | 4.7 | 28 | Citations (PDF) |
| 22 | Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer | 1.7 | 38 | Citations (PDF) |
| 23 | Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development | 2.5 | 41 | Citations (PDF) |
| 24 | Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress | 3.7 | 1 | Citations (PDF) |
| 25 | PRCosomes: pretty reactive complexes formed in liposomes | 4.0 | 19 | Citations (PDF) |
| 26 | Synthetic lethality in lung cancer and translation to clinical therapies | 29.8 | 27 | Citations (PDF) |
| 27 | Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma | 2.2 | 63 | Citations (PDF) |
| 28 | Abstract 1319: A novel formulation of CX-5461, a small-molecule inhibitor of rRNA synthesis, and its use for treatment of acute myeloid leukemia models | 0.6 | 4 | Citations (PDF) |
| 29 | Abstract 2206: Development and characterization of an injectable copper clioquinol formulation: repurposing of a topical antifungal for treatment of cancer 2016, , | | 1 | Citations (PDF) |
| 30 | Abstract 3914: Repurposing disulfiram for use as an anticancer drug: a story about metabolism and metal binding 2016, , | | 1 | Citations (PDF) |
| 31 | Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro | 2.5 | 12 | Citations (PDF) |
| 32 | Identification of breast cancer cell subtypes sensitive to ATG4B inhibition | 1.7 | 52 | Citations (PDF) |
| 33 | Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer | 1.5 | 6 | Citations (PDF) |
| 34 | Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer | 11.3 | 21 | Citations (PDF) |
| 35 | 3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents | 1.7 | 16 | Citations (PDF) |
| 36 | Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities | 2.6 | 14 | Citations (PDF) |
| 37 | Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer | 6.4 | 125 | Citations (PDF) |
| 38 | Harnessing The Potential of Lipid-Based Nanomedicines for Type-Specific Ovarian Cancer Treatments | 3.1 | 10 | Citations (PDF) |
| 39 | Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity | 6.4 | 25 | Citations (PDF) |
| 40 | Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model | 3.4 | 26 | Citations (PDF) |
| 41 | Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo | 2.5 | 59 | Citations (PDF) |
| 42 | Liposomes 2013, , 27-63 | | 11 | Citations (PDF) |
| 43 | Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model | 2.5 | 23 | Citations (PDF) |
| 44 | Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil | 2.5 | 26 | Citations (PDF) |
| 45 | Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer | 2.5 | 83 | Citations (PDF) |
| 46 | A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form | 3.2 | 144 | Citations (PDF) |
| 47 | A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer | 1.5 | 33 | Citations (PDF) |
| 48 | Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer | 2.6 | 25 | Citations (PDF) |
| 49 | Multivalent Rituximab Lipid Nanoparticles as Improved Lymphoma Therapies: Indirect Mechanisms of Action and
<i>In Vivo</i>
Activity | 3.1 | 16 | Citations (PDF) |
| 50 | Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors | 0.6 | 633 | Citations (PDF) |
| 51 | Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy | 11.3 | 62 | Citations (PDF) |
| 52 | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine | 3.0 | 47 | Citations (PDF) |
| 53 | The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity | 3.0 | 23 | Citations (PDF) |
| 54 | Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267 | 4.3 | 21 | Citations (PDF) |
| 55 | A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation | 0.6 | 102 | Citations (PDF) |
| 56 | Lipid-Based Nanoformulation of Irinotecan: Dual Mechanism of Action Allows for Combination Chemo/Angiogenic Therapy | 3.1 | 4 | Citations (PDF) |
| 57 | Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles | 11.3 | 77 | Citations (PDF) |
| 58 | The functional roles of poly(ethylene glycol)‐lipid and lysolipid in the drug retention and release from lysolipid‐containing thermosensitive liposomes in vitro and in vivo | 3.4 | 100 | Citations (PDF) |
| 59 | Characterization of Cationic Liposome Formulations Designed to Exhibit Extended Plasma Residence Times and Tumor Vasculature Targeting Properties | 3.4 | 33 | Citations (PDF) |
| 60 | Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer | 2.2 | 29 | Citations (PDF) |
| 61 | The Role of the Transition Metal Copper and the Ionophore A23187 in the Development of Irinophore C™ | 3.9 | 9 | Citations (PDF) |
| 62 | siRNA-Mediated Integrin-Linked Kinase Suppression: Nonspecific Effects of siRNA/Cationic Liposome Complexes Trigger Changes in the Expression of Phosphorylated-AKT and mTOR Independently of ILK Silencing | 3.8 | 8 | Citations (PDF) |
| 63 | Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy | 2.3 | 44 | Citations (PDF) |
| 64 | QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model | 5.0 | 57 | Citations (PDF) |
| 65 | Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging | 3.2 | 22 | Citations (PDF) |
| 66 | Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes | 4.9 | 54 | Citations (PDF) |
| 67 | A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention | 4.2 | 42 | Citations (PDF) |
| 68 | Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels | 1.7 | 37 | Citations (PDF) |
| 69 | Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival | 0.6 | 180 | Citations (PDF) |
| 70 | Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin | 6.4 | 44 | Citations (PDF) |
| 71 | Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors | 6.4 | 35 | Citations (PDF) |
| 72 | Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK) | 1.7 | 53 | Citations (PDF) |
| 73 | A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity | 1.3 | 5 | Citations (PDF) |
| 74 | Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs | 1.7 | 46 | Citations (PDF) |
| 75 | In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine | 4.2 | 28 | Citations (PDF) |
| 76 | Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo | 2.2 | 109 | Citations (PDF) |
| 77 | Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding | 2.2 | 281 | Citations (PDF) |
| 78 | Magnetic Resonance Imaging of Temperature-Sensitive Liposome Release: Drug Dose Painting and Antitumor Effects | 5.1 | 243 | Citations (PDF) |
| 79 | Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin | 2.5 | 16 | Citations (PDF) |
| 80 | Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice | 1.7 | 285 | Citations (PDF) |
| 81 | Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma | 0.6 | 29 | Citations (PDF) |
| 82 | A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model | 3.9 | 106 | Citations (PDF) |
| 83 | Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation | 3.9 | 39 | Citations (PDF) |
| 84 | Copper–topotecan complexation mediates drug accumulation into liposomes | 11.3 | 62 | Citations (PDF) |
| 85 | Chemodosimetry of in vivo tumor liposomal drug concentration using MRI | 3.1 | 112 | Citations (PDF) |
| 86 | Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy | 3.1 | 0 | Citations (PDF) |
| 87 | Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems | 3.0 | 16 | Citations (PDF) |
| 88 | Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival | 0.6 | 104 | Citations (PDF) |
| 89 | Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line | 2.3 | 12 | Citations (PDF) |
| 90 | A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model | 3.9 | 8 | Citations (PDF) |
| 91 | Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth | 6.6 | 95 | Citations (PDF) |
| 92 | Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese | 11.3 | 104 | Citations (PDF) |
| 93 | Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity | 11.3 | 35 | Citations (PDF) |
| 94 | The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations | 2.6 | 43 | Citations (PDF) |
| 95 | Preparation, Characterization, and Biological Analysis of Liposomal Formulations of Vincristine | 1.0 | 46 | Citations (PDF) |
| 96 | The Liposomal Formulation of Doxorubicin | 1.0 | 333 | Citations (PDF) |
| 97 | Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer | 6.4 | 29 | Citations (PDF) |
| 98 | Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction | 6.4 | 74 | Citations (PDF) |
| 99 | Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model | 4.3 | 25 | Citations (PDF) |
| 100 | In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading | 6.4 | 85 | Citations (PDF) |
| 101 | Liposomal Irinotecan | 6.4 | 70 | Citations (PDF) |
| 102 | An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes | 11.3 | 85 | Citations (PDF) |
| 103 | In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery | 3.1 | 164 | Citations (PDF) |
| 104 | pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol | 2.2 | 83 | Citations (PDF) |
| 105 | Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes | 3.2 | 44 | Citations (PDF) |
| 106 | HER-2/<i>neu</i>Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization | 2.9 | 24 | Citations (PDF) |
| 107 | Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model | 1.7 | 4 | Citations (PDF) |
| 108 | Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis | 2.2 | 32 | Citations (PDF) |
| 109 | Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes | 3.2 | 57 | Citations (PDF) |
| 110 | Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids | 3.5 | 35 | Citations (PDF) |
| 111 | Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids | 2.2 | 28 | Citations (PDF) |
| 112 | Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes | 2.2 | 57 | Citations (PDF) |
| 113 | Formation of transition metal–doxorubicin complexes inside liposomes | 2.2 | 144 | Citations (PDF) |
| 114 | Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids | 2.2 | 52 | Citations (PDF) |
| 115 | Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells | 4.9 | 11 | Citations (PDF) |
| 116 | Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes | 2.0 | 20 | Citations (PDF) |
| 117 | Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol) | 2.2 | 52 | Citations (PDF) |
| 118 | Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages | 2.2 | 106 | Citations (PDF) |
| 119 | Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes | 2.2 | 34 | Citations (PDF) |
| 120 | Title is missing! | 3.9 | 7 | Citations (PDF) |
| 121 | Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes | 1.5 | 16 | Citations (PDF) |
| 122 | Efficient Delivery of Antennapedia Homeodomain Fused to CTL Epitope with Liposomes into Dendritic Cells Results in the Activation of CD8+ T Cells | 0.6 | 51 | Citations (PDF) |
| 123 | Use of Poly(ethylene glycol)–Lipid Conjugates to Regulate the Surface Attributes and Transfection Activity of Lipid–DNA Particles 2000, 89, 652-663 | | 140 | Citations (PDF) |
| 124 | Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications | 3.8 | 26 | Citations (PDF) |
| 125 | Antibody Conjugation Methods for Active Targeting of Liposomes 2000, , 51-68 | | 19 | Citations (PDF) |
| 126 | Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems 2000, , 255-304 | | 0 | Citations (PDF) |
| 127 | Clinical and Preclinical Pharmacology of Liposomal Vincristine | 3.8 | 4 | Citations (PDF) |
| 128 | Liposomal Anticancer Drugs as Agents to be used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with two Encapsulated Drugs | 3.8 | 9 | Citations (PDF) |
| 129 | Intravenous Pretreatment with Empty pH Gradient Liposomes Alters the Pharmacokinetics and Toxicity of Doxorubicin through In Vivo Active Drug Encapsulation | 3.4 | 31 | Citations (PDF) |
| 130 | Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity | 18.1 | 112 | Citations (PDF) |
| 131 | Biological barriers to cellular delivery of lipid-based DNA carriers | 15.7 | 157 | Citations (PDF) |
| 132 | A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection | 2.2 | 39 | Citations (PDF) |
| 133 | Electrostatically Mediated Interactions between Cationic Lipid–DNA Particles and an Anionic Surface | 2.7 | 7 | Citations (PDF) |
| 134 | Cationic Liposome–Plasmid DNA Complexes Used for Gene Transfer Retain a Significant Trapped Volume | 3.4 | 11 | Citations (PDF) |
| 135 | Clearance properties of liposomes involving conjugated proteins for targeting | 15.7 | 44 | Citations (PDF) |
| 136 | Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection | 2.3 | 33 | Citations (PDF) |
| 137 | Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer | 2.3 | 56 | Citations (PDF) |
| 138 | Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine | 2.2 | 140 | Citations (PDF) |
| 139 | Characterization of Lipid DNA Interactions. I. Destabilization of Bound Lipids and DNA Dissociation | 0.4 | 79 | Citations (PDF) |
| 140 | Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations | 3.8 | 33 | Citations (PDF) |
| 141 | Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations 1998, , 29-49 | | 9 | Citations (PDF) |
| 142 | Human gene therapy: principles and modern advances | 0.0 | 1 | Citations (PDF) |
| 143 | Analysis of Cationic Liposome-mediated Interactions of Plasmid DNA with Murine and Human Melanoma Cells in Vitro | 2.3 | 28 | Citations (PDF) |
| 144 | Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology | 3.8 | 9 | Citations (PDF) |
| 145 | Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles | 11.0 | 171 | Citations (PDF) |
| 146 | An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin | 1.5 | 22 | Citations (PDF) |
| 147 | Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates | 15.7 | 29 | Citations (PDF) |
| 148 | Title is missing! | 3.9 | 53 | Citations (PDF) |
| 149 | Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes | 2.3 | 47 | Citations (PDF) |
| 150 | Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection | 3.2 | 34 | Citations (PDF) |
| 151 | Genetic allogenization of malignant melanoma | 0.8 | 5 | Citations (PDF) |
| 152 | Cationic Lipid Binding to DNA: Characterization of Complex Formation† | 2.9 | 103 | Citations (PDF) |
| 153 | Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes | 2.3 | 33 | Citations (PDF) |
| 154 | Plasmid DNA is Protected against Ultrasonic Cavitation-Induced Damage when Complexed to Cationic Liposomes | 3.4 | 62 | Citations (PDF) |
| 155 | LIPOSOMAL CYCLOSPORINE | 1.0 | 16 | Citations (PDF) |
| 156 | A model approach for assessing liposome targetingin vivo | 7.9 | 2 | Citations (PDF) |
| 157 | Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy | 3.8 | 49 | Citations (PDF) |
| 158 | Poly(ethylene glycol)-Modified Phospholipids Prevent Aggregation during Covalent Conjugation of Proteins to Liposomes | 3.9 | 55 | Citations (PDF) |
| 159 | The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: Implications for drug delivery | 2.2 | 41 | Citations (PDF) |
| 160 | Formation of Novel Hydrophobic Complexes between Cationic Lipids and Plasmid DNA | 2.9 | 114 | Citations (PDF) |
| 161 | A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo | 2.3 | 29 | Citations (PDF) |
| 162 | The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin | 3.8 | 35 | Citations (PDF) |
| 163 | Polyethylene Glycol Modified Phospholipids Stabilize Emulsions Prepared from Triacylglycerol † | 3.4 | 57 | Citations (PDF) |
| 164 | Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice | 2.3 | 48 | Citations (PDF) |
| 165 | Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs | 1.5 | 41 | Citations (PDF) |
| 166 | The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade | 2.7 | 23 | Citations (PDF) |
| 167 | Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia | 2.3 | 71 | Citations (PDF) |
| 168 | Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes | 2.3 | 62 | Citations (PDF) |
| 169 | The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey | 2.7 | 210 | Citations (PDF) |
| 170 | Liposomes with entrapped doxorubicin exhibit extended blood residence times | 2.2 | 95 | Citations (PDF) |
| 171 | Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients | 2.2 | 208 | Citations (PDF) |
| 172 | Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients | 2.7 | 40 | Citations (PDF) |
| 173 | A non-covalent method of attaching antibodies to liposomes | 2.2 | 60 | Citations (PDF) |
| 174 | Techniques for encapsulating bioactive agents into liposomes | 2.7 | 149 | Citations (PDF) |
| 175 | Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential | 2.2 | 138 | Citations (PDF) |
